published meta-analysis   sensitivity analysis   studies

potential COVID-19 treatments in COVID-19 mild to moderate - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsGS-US-540-5774, 10 days, 2020 0.77 [0.17; 3.50] GS-US-540-5774, 5 days, 2020 0.52 [0.09; 2.86] 0.65[0.21; 2.01]GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 202020%784moderatenot evaluable deathsdetailed resultsGS-US-540-5773 (Goldman), 2020 0.73 [0.37; 1.44] GS-US-540-5774, 10 days, 2020 0.76 [0.17; 3.40] GS-US-540-5774, 5 days, 2020 0.51 [0.09; 2.84] 0.70[0.39; 1.26]GS-US-540-5773 (Goldman), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 202030%1,193moderatenot evaluable deaths (time to event analysis only)detailed resultsGS-US-540-5774, 10 days, 2020 0.76 [0.17; 3.40] GS-US-540-5774, 5 days, 2020 0.51 [0.09; 2.84] 0.64[0.21; 1.98]GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 202020%796moderatenot evaluable clinical improvementdetailed resultsGS-US-540-5773 (Goldman), 2020 0.79 [0.61; 1.02] GS-US-540-5774, 10 days, 2020 1.16 [0.77; 1.74] GS-US-540-5774, 5 days, 2020 1.65 [1.09; 2.49] 1.12[0.72; 1.75]GS-US-540-5773 (Goldman), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020379%1,193moderatenot evaluable clinical improvement (14-day)detailed resultsGS-US-540-5773 (Goldman), 2020 1.53 [1.02; 2.29] GS-US-540-5774, 10 days, 2020 1.58 [1.01; 2.47] GS-US-540-5774, 5 days, 2020 1.56 [1.00; 2.44] 1.56[1.21; 1.99]GS-US-540-5773 (Goldman), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 202030%1,181moderatenot evaluable clinical improvement (28-day)detailed resultsGS-US-540-5774, 10 days, 2020 1.88 [1.03; 3.42] GS-US-540-5774, 5 days, 2020 1.75 [0.97; 3.17] 1.81[1.19; 2.76]GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 202020%784moderatenot evaluable clinical improvement (7-day)detailed resultsGS-US-540-5773 (Goldman), 2020 1.46 [0.95; 2.23] GS-US-540-5774, 10 days, 2020 1.03 [0.69; 1.53] GS-US-540-5774, 5 days, 2020 1.41 [0.94; 2.09] 1.27[1.01; 1.61]GS-US-540-5773 (Goldman), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 202030%1,181moderatenot evaluable clinical improvement (time to event analysis only)detailed resultsGS-US-540-5773 (Goldman), 2020 0.79 [0.61; 1.02] GS-US-540-5774, 10 days, 2020 1.16 [0.94; 1.44] GS-US-540-5774, 5 days, 2020 1.15 [0.93; 1.42] 1.03[0.81; 1.30]GS-US-540-5773 (Goldman), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020369%1,193moderatenot evaluable mechanical ventilationdetailed resultsGS-US-540-5774, 10 days, 2020 0.26 [0.03; 2.30] GS-US-540-5774, 5 days, 2020 0.13 [0.01; 2.45] 0.20[0.03; 1.16]GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 202020%784moderatenot evaluable recoverydetailed resultsGS-US-540-5773 (Goldman), 2020 0.81 [0.64; 1.03] GS-US-540-5774, 10 days, 2020 1.11 [0.90; 1.37] GS-US-540-5774, 5 days, 2020 1.18 [0.96; 1.45] 1.03[0.83; 1.28]GS-US-540-5773 (Goldman), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020366%1,193moderatenot evaluable serious adverse eventsdetailed resultsGS-US-540-5774, 10 days, 2020 0.55 [0.25; 1.23] GS-US-540-5774, 5 days, 2020 0.50 [0.22; 1.14] 0.53[0.30; 0.94]GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 202020%784moderatenot evaluable adverse eventsdetailed resultsGS-US-540-5774, 10 days, 2020 1.63 [1.09; 2.42] GS-US-540-5774, 5 days, 2020 1.21 [0.82; 1.80] 1.40[1.05; 1.87]GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 202024%784moderatenot evaluable serious adverse events (SAE), anydetailed resultsGS-US-540-5773 (Goldman), 2020 0.50 [0.32; 0.79] 0.50[0.32; 0.79]GS-US-540-5773 (Goldman), 202010%397NAnot evaluable0.05.01.0relative treatment effectwww.metaEvidence.org2024-10-31 23:54 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 90 - treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439 - roots T: 290